Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psoriatic arthritis
Pharma
UCB shares results for Bimzelx's PsA triumph over Skyrizi
In a head-to-head psoriatic arthritis trial, UCB's Bimzelx achieved reduced disease activity in 49% of patients vs. 38% of those on AbbVie's Skyrizi.
Kevin Dunleavy
May 19, 2026 11:27am
With win over AbbVie's Skyrizi, UCB's Bimzelx remains undefeated
Mar 11, 2026 11:29am
FDA expands label for BMS' Sotyktu to treat psoriatic arthritis
Mar 9, 2026 11:16am
UCB reaps the rewards of fast-growing Bimzelx
Feb 27, 2026 11:51am
Lilly touts Zepbound-Taltz combo after psoriasis trial victory
Feb 18, 2026 8:30am
Lilly touts Zepbound-Taltz combo in patients with obesity, PsA
Jan 8, 2026 2:00pm
